New data from the VOLITION study reveal that 89% of treatment-naïve individuals with HIV chose to switch to long-acting cabotegravir and rilpivirine after achieving viral suppression with oral DTG/3TC ...

The cross-asset moves come at the end of a week marked by market jitters over speculation that President Donald Trump might ...